Onconova Therapeutics Announces First Participant In Investigator-Sponsored Phase 2 Trial

Onconova Therapeutics announced that the first participant has been dosed in an investigator-sponsored Phase 2 trial of oral rigosertib plus the PD-1 inhibitor pembrolizumab in patients with metastatic melanoma who have progressed on prior PD-1/L1 inhibitor therapy.

Read the May 25 press release